M1 and M2 macrophage proteolytic and angiogenic profile analysis in atherosclerotic patients reveals a distinctive profile in type 2 diabetes

Diabetes and Vascular Disease Research

Volumn 12, Issue 4, 2015, Pages 279-289

  Roma Lavisse, Charlotte ^a   Tagzirt, Madjid ^a   Zawadzki, Christophe ^a,b   Lorenzi, Rodrigo ^a   Vincentelli, André ^a,b   Haulon, Stephan ^b   Juthier, Francis ^a,b   Rauch, Antoine ^a,b   Corseaux, Delphine ^a   Staels, Bart ^a   Jude, Brigitte ^a,b   Van Belle, Eric ^a,b   Susen, Sophie ^a,b   Chinetti Gbaguidi, Giulia ^a   Dupont, Annabelle ^a,b  

^a UNIV LILLE   (France)

^b LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

angiogenesis; atherosclerosis; diabetes; Macrophage polarization; plaque vulnerability; proteolysis

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; FIBRIC ACID DERIVATIVE; GELATINASE B; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; INTERLEUKIN 1BETA; INTERLEUKIN 4; ORAL ANTIDIABETIC AGENT; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE FACTOR PATHWAY INHIBITOR; TISSUE INHIBITOR OF METALLOPROTEINASE 1; VASCULOTROPIN; BLOOD CLOTTING FACTOR 13; CD200R1 PROTEIN, HUMAN; CELL SURFACE RECEPTOR; FACTOR XIII SUBUNIT A; GLYCOPROTEIN; HOMING RECEPTOR; IL10 PROTEIN, HUMAN; IL1B PROTEIN, HUMAN; INTERLEUKIN 10; LECTIN; MANNOSE BINDING LECTIN; MANNOSE RECEPTOR; MEMBRANE ANTIGEN; MMP9 PROTEIN, HUMAN; NERVE CELL ADHESION MOLECULE; SERPINE1 PROTEIN, HUMAN; STAB1 PROTEIN, HUMAN; TIMP1 PROTEIN, HUMAN; TISSUE-FACTOR-PATHWAY INHIBITOR 2; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ANGIOGENESIS; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MACROPHAGE; MACROPHAGE CULTURE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PHENOTYPE; PROTEIN DEGRADATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ANGIOCARDIOGRAPHY; BRAIN ANGIOGRAPHY; CAROTID ARTERY DISEASE; CASE CONTROL STUDY; COMPLICATION; CORONARY ARTERY DISEASE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; NEOVASCULARIZATION (PATHOLOGY); PROSPECTIVE STUDY; RADIOGRAPHY;

AGED; ANTIGENS, SURFACE; ATHEROSCLEROSIS; CAROTID ARTERY DISEASES; CASE-CONTROL STUDIES; CELL ADHESION MOLECULES, NEURONAL; CEREBRAL ANGIOGRAPHY; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; DIABETES MELLITUS, TYPE 2; FACTOR XIII; FEMALE; GENE EXPRESSION REGULATION; GLYCOPROTEINS; HUMANS; INTERLEUKIN-10; INTERLEUKIN-1BETA; LECTINS, C-TYPE; MACROPHAGES; MALE; MANNOSE-BINDING LECTINS; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; PHENOTYPE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROSPECTIVE STUDIES; PROTEOLYSIS; RECEPTORS, CELL SURFACE; RECEPTORS, LYMPHOCYTE HOMING; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84937000563     PISSN: 14791641     EISSN: 17528984     Source Type: Journal    
DOI: 10.1177/1479164115582351     Document Type: Article

References (35)

1. Dale AC, Vatten LJ, Nilsen TI,. Secular decline in mortality from coronary heart disease in adults with diabetes mellitus: cohort study. BMJ 2008; 337: a236.
2. Moreno PR, Murcia AM, Palacios IF,. Coronary composition and macrophage infiltration in atherectomy specimens from patients with diabetes mellitus. Circulation 2000; 102: 2180-2184.
3. Ramos MA, Kuzuya M, Esaki T,. Induction of macrophage VEGF in response to oxidized LDL and VEGF accumulation in human atherosclerotic lesions. Arterioscler Thromb Vasc Biol 1998; 18: 1188-1196.
4. Meisel SR, Xu XP, Edgington TS,. Differentiation of adherent human monocytes into macrophages markedly enhances tissue factor protein expression and procoagulant activity. Atherosclerosis 2002; 161: 35-43.
5. Newby AC,. Metalloproteinase expression in monocytes and macrophages and its relationship to atherosclerotic plaque instability. Arterioscler Thromb Vasc Biol 2008; 28: 2108-2114.
6. Gordon S,. Alternative activation of macrophages. Nat Rev Immunol 2003; 3: 23-35.
7. Mosser DM,. The many faces of macrophage activation. J Leukoc Biol 2003; 73: 209-212.
8. Bouhlel MA, Derudas B, Rigamonti E,. PPARgamma activation primes human monocytes into alternative M2 macrophages with anti-inflammatory properties. Cell Metab 2007; 6: 137-143.
9. Chinetti-Gbaguidi G, Colin S, Staels B,. Macrophages subsets in atherosclerosis. Nat Rev Cardiol 2015; 12: 10-17.
10. Fadini GP, Cappellari R, Mazzucato M,. Monocyte-macrophage polarization balance in pre-diabetic individuals. Acta Diabetol 2013; 50: 977-982.
11. Chinetti G, Griglio S, Antonucci M,. Activation of peroxisome proliferator-activated receptors alpha and gamma induces apoptosis of human monocyte-derived macrophages. J Biol Chem 1998; 273: 25573-25580.
12. Zawadzki C, Chatelain N, Delestre M,. Tissue factor pathway inhibitor-2 gene methylation is associated with low expression in carotid atherosclerotic plaques. Atherosclerosis 2009; 204: e4-e14.
13. Apostolakis S, Vogiatzi K, Krambovitis E,. IL-1 cytokines in cardiovascular disease: diagnostic, prognostic and therapeutic implications. Cardiovasc Hematol Agents Med Chem 2008; 6: 150-158.
14. Cho KY, Miyoshi H, Kuroda S,. The phenotype of infiltrating macrophages influences arteriosclerotic plaque vulnerability in the carotid artery. J Stroke Cerebrovasc Dis 2013; 22: 910-918.
15. Visse R, Nagase H,. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 2003; 92: 827-839.
16. Herman MP, Sukhova GK, Kisiel W,. Tissue factor pathway inhibitor-2 is a novel inhibitor of matrix metalloproteinases with implications for atherosclerosis. J Clin Invest 2001; 107: 1117-1126.
17. Oh CK, Ariue B, Alban RF,. PAI-1 promotes extracellular matrix deposition in the airways of a murine asthma model. Biochem Biophys Res Commun 2002; 294: 1155-1160.
18. Zawadzki C, Susen S, Richard F,. Dyslipidemia shifts the tissue factor/tissue factor pathway inhibitor balance toward increased thrombogenicity in atherosclerotic plaques: evidence for a corrective effect of statins. Atherosclerosis 2007; 195: e117-e125.
19. Lupu F, Bergonzelli GE, Heim DA,. Localization and production of plasminogen activator inhibitor-1 in human healthy and atherosclerotic arteries. Arterioscler Thromb 1993; 13: 1090-1100.
20. Sobel BE, Woodcock-Mitchell J, Schneider DJ,. Increased plasminogen activator inhibitor type 1 in coronary artery atherectomy specimens from type 2 diabetic compared with nondiabetic patients: a potential factor predisposing to thrombosis and its persistence. Circulation 1998; 97: 2213-2221.
21. Caplice NM, Mueske CS, Kleppe LS,. Presence of tissue factor pathway inhibitor in human atherosclerotic plaques is associated with reduced tissue factor activity. Circulation 1998; 98: 1051-1057.
22. Hasita H, Komohara Y, Okabe H,. Significance of alternatively activated macrophages in patients with intrahepatic cholangiocarcinoma. Cancer Sci 2010; 101: 1913-1919.
23. Jetten N, Verbruggen S, Gijbels MJ,. Anti-inflammatory M2, but not pro-inflammatory M1 macrophages promote angiogenesis in vivo. Angiogenesis 2014; 17: 109-118.
24. Virmani R, Kolodgie FD, Burke AP,. Atherosclerotic plaque progression and vulnerability to rupture: angiogenesis as a source of intraplaque hemorrhage. Arterioscler Thromb Vasc Biol 2005; 25: 2054-2061.
25. Yunoki K, Naruko T, Komatsu R,. Enhanced expression of haemoglobin scavenger receptor in accumulated macrophages of culprit lesions in acute coronary syndromes. Eur Heart J 2009; 30: 1844-1852.
26. Brochériou I, Maouche S, Durand H,. Antagonistic regulation of macrophage phenotype by M-CSF and GM-CSF: implication in atherosclerosis. Atherosclerosis 2011; 214: 316-324.
27. Waldo SW, Li Y, Buono C,. Heterogeneity of human macrophages in culture and in atherosclerotic plaques. Am J Pathol 2008; 172: 1112-1126.
28. Bories G, Caiazzo R, Derudas B,. Impaired alternative macrophage differentiation of peripheral blood mononuclear cells from obese subjects. Diab Vasc Dis Res 2012; 9: 189-195.
29. Nicholls SJ, Tuzcu EM, Kalidindi S,. Effect of diabetes on progression of coronary atherosclerosis and arterial remodeling: a pooled analysis of 5 intravascular ultrasound trials. J Am Coll Cardiol 2008; 52: 255-262.
30. Schuyler CA, Ta NN, Li Y,. Insulin treatment attenuates diabetes-increased atherosclerotic intimal lesions and matrix metalloproteinase 9 expression in apolipoprotein E-deficient mice. J Endocrinol 2011; 210: 37-46.
31. Olson FJ, Strömberg S, Hjelmgren O,. Increased vascularization of shoulder regions of carotid atherosclerotic plaques from patients with diabetes. J Vasc Surg 2011; 54: 1324-1331.
32. Hayden MR, Tyagi SC,. Vasa vasorum in plaque angiogenesis, metabolic syndrome, type 2 diabetes mellitus, and atheroscleropathy: a malignant transformation. Cardiovasc Diabetol 2004; 3: 1.
33. Stöger JL, Gijbels MJ, van der Velden S,. Distribution of macrophage polarization markers in human atherosclerosis. Atherosclerosis 2012; 225: 461-468.
34. Saeed S, Quintin J, Kerstens HH,. Epigenetic programming of monocyte-to-macrophage differentiation and trained innate immunity. Science 2014; 345: 1251086.
35. Bekkering S, Joosten LA, van der Meer JW,. The epigenetic memory of monocytes and macrophages as a novel drug target in atherosclerosis. Clin Ther. Epub ahead of print 19 2015. DOI: 10.1016/j.clinthera.2015.01.008.